Design and development of a bispecific antibody targeting BAFF and IL-17 for systemic lupus erythematosus treatment
The bsscFv exhibited potent neutralizing activity in vitro and therapeutic efficacy in vivo, suggesting it as a promising bispecific therapeutic agent for the treatment of SLE. Further studies are warranted to explore its clinical potential.
Authors
- Gaiping Zhang (ORCID: https://orcid.org/0000-0002-3834-9975)
- Yankai Liu (ORCID: https://orcid.org/0000-0002-6559-2348)
- Jingming Zhou (ORCID: https://orcid.org/0000-0003-2079-1420)
- Hongliang Liu (ORCID: https://orcid.org/0000-0002-7533-6874)
- Aiping Wang (ORCID: https://orcid.org/0000-0003-1661-8174)
- Cheng Xin (ORCID: https://orcid.org/0009-0009-4586-7242)
- Chao Liang (ORCID: https://orcid.org/0000-0001-6082-1159)
- Yumei Chen (ORCID: https://orcid.org/0000-0002-0241-7577)
- Yanhua Qi (ORCID: https://orcid.org/0000-0002-8796-3226)
- Xifang Zhu (ORCID: https://orcid.org/0000-0002-7504-3350)
Institutions
- Peking University (CN)
- Zhengzhou University (CN)
- Henan University of Engineering (CN)
Publication Details
- Journal
- BMC Biology
- Published
- 2025-09-29
- DOI
- https://doi.org/10.1186/s12915-025-02398-2
- Citations
- 1
- Primary Topic
- Monoclonal and Polyclonal Antibodies Research
- Type
- article
- Field-Weighted Citation Impact
- 1.36
Funders
- Zhengzhou University